Memorial Sloan-Kettering Cancer Center - Recruiting 16 years or older. - A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of CTLA-4 Blockade for BRAF Mutant Melanoma.
Genentech - Recruiting 16 years or older. - An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E.
Fred Hutchinson Cancer Research Center - Recruiting 18 years or older. - Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.
Hoffmann-La Roche - Recruiting 12 years to 17 years. - An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Mutations.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma.